ACN Newswire: latest releases

News releases provided by ACN Newswire - Asia Corporate News Network ACN Newswire - Asia Corporate News Network.

Lasting Antiviral Effect against Covid-19 virus (SARS-CoV-2) TAKEX CLEAN EXTRA

Klang Valley, Kuala Lumpur, Peninsular Malaysia, Geography of Malaysia, Geography of Asia, Malaysian cuisine, Asia
Thursday, January 28, 2021 - 1:00am

TAKEX CLEAN EXTRA used in this test is a food-grade ethanol sanitizer containing extract from bamboo sheath.

Key Points: 
  • TAKEX CLEAN EXTRA used in this test is a food-grade ethanol sanitizer containing extract from bamboo sheath.
  • It also provides assurance to the users as TAKEX CLEAN EXTRA is Halal certified by JAKIM, the Malaysian government certification body, which is recognized in other countries as well.
  • TAKEX CLEAN EXTRA is manufactured in Kuala Lumpur and now on sale in Malaysia, Singapore & Indonesia (product name: MAZTEX CLEAN EXTRA) and Thailand (product name: TAKETSUYU).
  • It is confirmed that 99.99% of the virus was inactived after 15 days of TAKEX CLEAN EXTRA application.

China Biotech Services LY007 Cell Injection Obtained Clinical Trial Approval Letter

Health sciences, Health, Longyao, Clinical trial, Life sciences
Thursday, January 28, 2021 - 12:50am

HONG KONG, Jan 28, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao") received an approval letter from the National Medical Products Administration for a clinical trial of the Company's LY007 Cellular Injection on January 21, 2021, which is registered as a Class I new drug.

Key Points: 
  • HONG KONG, Jan 28, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao") received an approval letter from the National Medical Products Administration for a clinical trial of the Company's LY007 Cellular Injection on January 21, 2021, which is registered as a Class I new drug.
  • It is currently the first and only CD20-targeted CAR-T product whose application for a registered clinical trial has been approved in China.
  • According to the clinical trial application of LY007 Cellular Injection, Shanghai Longyao will commence Phase I clinical trial and study of LY007 Cellular Injection based on the submitted proposal.The National Medical Products Administration's approval of Shanghai Longyao's clinical trial application for LY007 Cellular Injection demonstrates Shanghai Longyao's capabilities in the research and development of immunocellular drugs.
  • According to a research report issued by China Merchants Bank on CH BIOTECH SER on November 20, 2020, the analyst recommended to watch for the results of the LY007 Cellular Injection clinical trial which could enhance the company's market value.

Broncus Holding Corporation Closed Series D Financing

Medical diagnosis, Medical terminology, Nosology
Thursday, January 28, 2021 - 12:30am

HONG KONG, Jan 28, 2021 - (ACN Newswire) - Broncus Holding Corporation ("Broncus"), a global leader in diagnostic and therapeutic technology for lung diseases, announced today the closing of a Series D round of funding led by FountainVest Partners.

Key Points: 
  • HONG KONG, Jan 28, 2021 - (ACN Newswire) - Broncus Holding Corporation ("Broncus"), a global leader in diagnostic and therapeutic technology for lung diseases, announced today the closing of a Series D round of funding led by FountainVest Partners.
  • Broncus is dedicated to the development of diagnostic and therapeutic technology for lung diseases with focus on the diagnosis of lung cancer and the treatment of emphysema.
  • Owning more than 200 patents, Broncus has built a comprehensive and robust pipeline of patented technologies using a disciplined approach.
  • Leveraging FountainVest's resource within the healthcare sector, we look forward to partnering with Broncus to explore further growth opportunities both domestically and globally."

Blockpass Provides Powerful On-chain KYC(TM) Utility for EasyFi DeFi Lending Platform

Identity management systems, Identity verification service, Internet privacy, Decentralized finance, Defi
Thursday, January 28, 2021 - 12:00am

The partnership features a powerful use case for on-chain KYC data via a network consisting of Blockpass, Chainlink, Matic and EasyFi, enabling the realization of decentralized and compliant lending and borrowing of digital assets over public networks.

Key Points: 
  • The partnership features a powerful use case for on-chain KYC data via a network consisting of Blockpass, Chainlink, Matic and EasyFi, enabling the realization of decentralized and compliant lending and borrowing of digital assets over public networks.
  • Enabling lower cost transactions, a deeper liquidity pool and real-world integrations, EasyFi hopes to be the catalyst for the mass adoption of DeFi.
  • Blockpass is a digital identity verification provider which offers a one-click compliance gateway to financial services and other regulated industries.
  • For businesses and merchants, Blockpass is a comprehensive KYC & AML SaaS that requires no integration and no setup cost.

The republication and redistribution of any and/or all of the ACN Newswire Content Feed displayed on this is website is strictly prohibited.